)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
Jyong Biotech
Jyong Biotech (MENS) investor relations material
Jyong Biotech Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary15 May, 2026
Executive summary
Focused on developing and commercializing plant-derived drugs for urinary system diseases, with three main candidates: Botreso® (BPH/LUTS), PCP (prostate cancer prevention), and IC (interstitial cystitis).
Completed IPO in June 2025, raising $17.8 million net proceeds.
No product revenue generated; operations funded by equity, loans, and related party transactions.
Financial highlights
Net losses: $4.7M (2025), $3.0M (2024), $4.4M (2023); accumulated deficit $37.8M as of Dec 31, 2025.
R&D expenses: $813K (2025), $927K (2024), $1.1M (2023); G&A expenses: $1.7M (2025), $1.1M (2024), $1.7M (2023).
Cash used in operations: $3.0M (2025), $3.6M (2024), $2.6M (2023); cash and equivalents: $1.2M at end of 2025.
No revenue recognized in 2023–2025.
Outlook and guidance
Significant additional funding required to continue operations and clinical development; substantial doubt about ability to continue as a going concern.
Plans to pursue further public offerings, credit facilities, or strategic collaborations.
Expenses expected to increase as clinical programs advance and public company costs rise.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jyong Biotech
- Biotech with no revenue seeks Nasdaq IPO to fund trials, facing high financial and legal risks.MENS
Registration Filing29 Nov 2025 - Pre-revenue biotech targeting urinary diseases seeks Nasdaq IPO amid high financial and regulatory risk.MENSRegistration Filing29 Nov 2025
- Pre-revenue biotech seeks Nasdaq IPO to fund clinical trials amid high regulatory and legal risks.MENSRegistration Filing29 Nov 2025
- Biotech seeks Nasdaq IPO to fund clinical trials amid high financial and regulatory risk.MENSRegistration Filing29 Nov 2025
- Pre-revenue biotech seeks Nasdaq IPO to fund clinical trials amid high regulatory and legal risks.MENSRegistration Filing29 Nov 2025
- Pre-revenue biotech seeks Nasdaq IPO to fund clinical trials amid high financial and legal risks.MENSRegistration Filing29 Nov 2025
- Biotech seeks Nasdaq IPO to fund clinical trials amid high regulatory and financial risk.MENSRegistration Filing29 Nov 2025
- Biotech seeks $17.8M IPO to fund clinical trials amid high regulatory and legal risks.MENSRegistration Filing29 Nov 2025
- Biotech with no revenue, large deficits, and legal risks seeks IPO to fund clinical trials.MENSRegistration Filing29 Nov 2025
Next Jyong Biotech earnings date
Q1 202624 Jul, 2026
Jyong Biotech
Next Jyong Biotech earnings date
Q1 202624 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage